Form 4: 4D Molecular Therapeutics Legal Officer Sells Shares

4D Molecular Therapeutics' Chief Legal Officer, Scott Bizily, sold 2,407 shares of common stock at $8 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, Inc. (FDMT), reported a transaction involving the company's common stock.
• On September 23, 2025, Bizily sold 2,407 shares of common stock.
• The shares were sold at a price of $8 per share.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on June 6, 2025.
• Following this transaction, Bizily's direct beneficial ownership stands at 7,596 shares of the company's common stock.
• The beneficial ownership figure of 7,596 shares includes 3,222 shares acquired through the company's Employee Stock Purchase Plan, which is exempt under Rule 16b-3.

Sentiment

Score: 5

Explanation: Neutral. The sale was pre-planned under a 10b5-1 plan, which reduces the negative signaling typically associated with insider sales. The beneficial ownership still includes a significant number of shares, including recent ESPP purchases, balancing the disposition.

Positives

• The reporting person's beneficial ownership includes 3,222 shares purchased under the Employee Stock Purchase Plan, indicating continued investment in the company.

Negatives

• An insider, the Chief Legal Officer, disposed of 2,407 shares of common stock.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

This insider transaction is a routine disclosure for publicly traded companies and does not inherently reflect broader industry trends. Insider sales under 10b5-1 plans are common for executives managing personal finances.

Related Party Transactions

• The transaction involves an insider (Chief Legal Officer) selling company stock, which is a common type of related party dealing.

Stakeholder Impact

• Shareholders may note the insider sale, but the context of a pre-arranged 10b5-1 plan suggests it is a planned liquidity event rather than a reaction to new material non-public information, thus mitigating potential negative sentiment.

Key Dates

Recommendation

The sale by the Chief Legal Officer was conducted under a pre-arranged 10b5-1 trading plan, which typically indicates a planned liquidity event rather than a reaction to new material non-public information. While insider sales can sometimes be a negative signal, the pre-planned nature mitigates this concern. Furthermore, the reporting person also acquired shares through an Employee Stock Purchase Plan, suggesting continued confidence. Therefore, this filing alone does not warrant a change from a 'hold' position.

Keywords

4D Molecular Therapeutics, FDMT, Scott Bizily, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Chief Legal Officer, Employee Stock Purchase Plan